…
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -1.79M | -20.29M | -40.58M | -77.62M | -32.57M |
| Net income | -5.49M | -20.29M | -39.21M | -67.64M | -30.28M |
| Selling general administrative | 8.74M | 0.01M | 10.79M | 14.47M | 14.94M |
| Selling and marketing expenses | - | 9.19M | - | - | - |
| Gross profit | -0.08M | -0.08M | - | - | - |
| Reconciled depreciation | 0.08M | 0.08M | 0.53M | 0.19M | 0.17M |
| Ebit | -1.56M | -20.24M | -41.33M | -77.28M | -30.32M |
| Ebitda | -1.47M | -20.16M | -21.08M | -32.49M | -32.44M |
| Depreciation and amortization | 0.08M | 0.08M | 20.25M | 44.79M | -2.12M |
| Non operating income net other | - | - | - | - | -2.12M |
| Operating income | -25.02M | -17.54M | -41.33M | -77.28M | -30.32M |
| Other operating expenses | 25.02M | 17.54M | 21.89M | 32.26M | 30.32M |
| Interest expense | 0.23M | 0.05M | 0.05M | 0.11M | 0.12M |
| Tax provision | -0.01M | 0.00M | -1.37M | -9.99M | - |
| Interest income | 0.07M | 0.33M | 0.11M | 0.09M | 0.12M |
| Net interest income | -0.17M | 0.28M | 0.06M | -0.02M | -0.00M |
| Income tax expense | 3.69M | -0.09M | -1.37M | -9.99M | -2.29M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 24.93M | 17.46M | 21.89M | 32.26M | 30.32M |
| Cost of revenue | 0.08M | 0.08M | - | - | - |
| Total other income expense net | 23.23M | -2.75M | 0.76M | -0.34M | -2.25M |
| Net income from continuing ops | -1.79M | -20.29M | -39.21M | -67.64M | -32.57M |
| Net income applicable to common shares | - | - | - | -67.64M | -32.57M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 27.88M | 32.41M | 37.95M | 74.79M | 112.89M |
| Intangible assets | 24.13M | 25.25M | 25.25M | 32.07M | 77.09M |
| Other current assets | 0.80M | 1.06M | 1.21M | 1.14M | 1.19M |
| Total liab | 17.88M | 29.02M | 27.94M | 32.91M | 43.33M |
| Total stockholder equity | 10.00M | 3.39M | 10.01M | 41.88M | 69.55M |
| Deferred long term liab | - | - | - | - | 16.78M |
| Other current liab | 2.41M | 2.52M | 1.55M | 3.41M | 3.81M |
| Common stock | 0.30M | 0.01M | - | 0.03M | 0.02M |
| Capital stock | 0.00M | 0.01M | 0.00M | 0.03M | 0.02M |
| Retained earnings | -846.61M | -844.82M | -824.53M | -785.32M | -717.69M |
| Other liab | - | - | - | 10.91M | 19.58M |
| Good will | - | 0.00M | 3.06M | 15.68M | 15.68M |
| Other assets | - | 0.00M | - | 0.15M | 0.15M |
| Cash | 1.78M | 4.32M | 6.17M | 22.35M | 16.93M |
| Total current liabilities | 5.72M | 4.00M | 2.46M | 4.92M | 6.13M |
| Net debt | 0.04M | 12.51M | -3.89M | -19.45M | -13.15M |
| Short term debt | 1.17M | 0.67M | 0.66M | 0.82M | 1.16M |
| Short long term debt | 0.66M | 0.23M | 0.25M | 0.29M | 0.35M |
| Short long term debt total | 1.82M | 16.83M | 2.28M | 2.89M | 3.78M |
| Other stockholder equity | 856.61M | 848.21M | 834.54M | 827.18M | 787.22M |
| Property plant equipment | - | - | - | 3.39M | 1.84M |
| Total current assets | 2.57M | 5.38M | 7.38M | 23.49M | 18.12M |
| Net tangible assets | - | - | - | -5.87M | -23.22M |
| Long term debt | - | - | - | - | 2.42M |
| Accounts payable | 1.88M | 0.81M | 0.25M | 0.69M | 1.16M |
| Accumulated other comprehensive income | 0.00M | 0.00M | - | - | - |
| Common stock total equity | - | - | - | - | 0.02M |
| Retained earnings total equity | - | - | - | - | -717.69M |
| Treasury stock | - | - | - | - | -3.05M |
| Non currrent assets other | 0.01M | 0.15M | 0.15M | 0.15M | 0.15M |
| Non current assets total | 25.30M | 27.03M | 30.58M | 51.30M | 94.77M |
| Capital lease obligations | 1.16M | 1.60M | 2.03M | 2.60M | 1.01M |
| Long term debt total | - | - | - | - | 2.42M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.01M | -0.01M | 0.20M | -0.28M | -0.29M |
| Change to liabilities | - | - | - | -0.47M | -0.55M |
| Total cashflows from investing activities | -0.01M | -0.01M | - | -0.28M | -0.29M |
| Net borrowings | 1.26M | -0.80M | - | -3.87M | -3.23M |
| Total cash from financing activities | 12.73M | 11.60M | 3.08M | 29.36M | 19.96M |
| Change to operating activities | - | - | - | 0.41M | -0.78M |
| Net income | -1.79M | -20.29M | -39.21M | -67.64M | -32.57M |
| Change in cash | -2.68M | -1.86M | -16.18M | 5.42M | -5.65M |
| Begin period cash flow | 4.47M | 6.33M | 22.50M | 17.08M | 22.73M |
| End period cash flow | 1.79M | 4.47M | 6.33M | 22.50M | 17.08M |
| Total cash from operating activities | -15.40M | -13.44M | -19.45M | -23.66M | -25.32M |
| Issuance of capital stock | 5.49M | 11.55M | 4.25M | 32.23M | 20.25M |
| Depreciation | 0.08M | 0.08M | 0.53M | 0.19M | 0.17M |
| Dividends paid | 0.66M | 0.00M | - | - | - |
| Sale purchase of stock | -1.88M | 0.00M | - | - | 20.39M |
| Other cashflows from financing activities | 6.65M | 0.84M | 0.20M | 1.00M | 3.49M |
| Change to netincome | - | - | - | 43.84M | 8.41M |
| Capital expenditures | 0.01M | 0.01M | 0.01M | 0.28M | 0.29M |
| Cash flows other operating | - | - | - | - | -0.89M |
| Cash and cash equivalents changes | - | - | - | - | -5.65M |
| Change in working capital | 1.37M | 2.02M | -1.78M | -0.06M | -1.33M |
| Stock based compensation | 0.46M | 1.28M | 3.09M | 7.24M | 5.68M |
| Other non cash items | -15.31M | 3.48M | 19.28M | 46.59M | 1.59M |
| Free cash flow | -15.41M | -13.45M | -19.46M | -23.94M | -25.61M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WINT Windtree Therapeutics Inc |
0.00 50.00% |
0.00 | - | 0.37 | 660.53 | 0.61 | 706.08 | 0.01 |
| NVO Novo Nordisk A/S |
-0.34 0.86% |
39.09 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.95 1.30% |
529.50 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-18.50 1.96% |
927.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig E. Fraser | Pres, CEO & Director | 1965 |
| Mr. John P. Hamill CPA | Sr. VP, CFO, Treasurer & Corp. Sec. | 1964 |
| Dr. Steven G. Simonson | Sr. VP & Chief Medical Officer | 1959 |
| Mr. Eric L. Curtis M.B.A. | Sr. VP & COO | 1969 |
| Mr. George Cox | VP of Technical Operations | 1952 |
| Ms. Diane Carman Esq. | Sr. VP & Gen. Counsel | 1969 |
| Dr. Pratap Paruchuru | Exec. Director of Clinical Devel. | NA |
| Ms. Tracy Rarick | Head of Operations & Program Management | NA |
| Dr. Ronald L. Dundore | Exec. Director of Regulatory Affairs & Quality | 1955 |
| Mr. Craig E. Fraser | Chairman, President, CEO & Interim Principal Officer | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.